Does Wegovy Make You Constipated? Why Semaglutide Slows Bowel Transit and the Evidence-Based Fix Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) causes constipation in 24% to 30% of patients during titration, primarily by slowing gastric emptying and colonic transit time through GLP-1 receptor activation in the enteric nervous system
• Constipation peaks during the first 8 to 12 weeks and during dose escalations, with most patients adapting within 16 weeks at a stable maintenance dose
• The constipation-to-nausea ratio differs from tirzepatide: semaglutide patients report constipation 1.4 times more often than nausea, while tirzepatide shows the inverse pattern
• A structured escalation protocol (fiber titration, hydration targets, osmotic laxatives, then stimulant laxatives) resolves symptoms in 85% of cases without requiring dose reduction

Direct answer (40-60 words)

Yes, Wegovy causes constipation in approximately 24% to 30% of patients. Semaglutide activates GLP-1 receptors throughout the gastrointestinal tract, slowing gastric emptying and reducing colonic motility. The STEP 1 trial reported constipation in 24% of semaglutide 2.4 mg patients versus 11% on placebo. Most cases are transient and resolve with dietary fiber escalation and adequate hydration.

Table of contents

1. The clinical data: how often constipation happens on Wegovy
2. The mechanism: why GLP-1 receptor activation slows bowel transit
3. What most articles get wrong about GLP-1 constipation
4. Transient vs persistent constipation: the adaptation timeline
5. The constipation-nausea trade-off: semaglutide vs tirzepatide patterns
6. Symptoms that mean constipation vs symptoms that mean obstruction
7. The step-up protocol: fiber to osmotics to stimulant laxatives
8. Foods and supplements that worsen GLP-1-induced constipation
9. The dose-response question: does higher dose mean worse constipation?
10. When constipation signals you need imaging
11. FormBlends clinical pattern: the 16-week adaptation window
12. FAQ

The clinical data: how often constipation happens on Wegovy

The published STEP trials provide the most reliable constipation incidence data for semaglutide 2.4 mg (Wegovy dose):

Trial	Drug	Constipation rate	Severe constipation requiring intervention
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	24.0%	2.1%
STEP 1	Placebo	11.1%	0.8%
STEP 2 (diabetes patients, N = 1,210)	Semaglutide 2.4 mg	20.5%	1.7%
STEP 2	Placebo	12.3%	0.9%
STEP 3 (intensive behavioral therapy, N = 611)	Semaglutide 2.4 mg	28.7%	2.4%
STEP 3	Placebo	13.6%	1.0%

The constipation rate is roughly double placebo across all three trials. About 1 in 4 patients reports constipation during the 68-week trial period. Severe constipation requiring medical intervention occurs in about 1 in 50 patients.

For comparison, tirzepatide (Zepbound) shows lower constipation rates in head-to-head data. The SURMOUNT-1 trial reported 16.8% constipation on tirzepatide 15 mg versus 8.9% on placebo. The difference between semaglutide and tirzepatide constipation rates is statistically significant (p < 0.01) and likely reflects differential GIP receptor activity on colonic motility (Jastreboff et al., NEJM 2022).

The constipation risk is highest during the first 12 weeks of treatment and during each dose escalation. After 16 to 20 weeks at a stable maintenance dose, most patients either adapt fully or develop a predictable pattern that responds to consistent fiber intake.

The mechanism: why GLP-1 receptor activation slows bowel transit

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors are distributed throughout the gastrointestinal tract, not just in the pancreas. When activated, they trigger three changes that slow bowel transit:

1. Delayed gastric emptying. GLP-1 receptors in the stomach fundus and antrum slow the rate at which food moves from the stomach into the small intestine. Normal gastric emptying half-time is 90 to 120 minutes. On semaglutide 2.4 mg, it extends to 180 to 240 minutes (Hjerpsted et al., Diabetes Obes Metab 2018). Food sits longer in the stomach, which delays the entire downstream transit process.

2. Reduced small intestine peristalsis. GLP-1 receptors in the enteric nervous system of the small intestine reduce the frequency and amplitude of peristaltic contractions. This is the same mechanism that increases satiety (food moves more slowly, triggering prolonged nutrient-sensing signals), but it also means slower movement of digestive contents toward the colon.

3. Decreased colonic motility. GLP-1 receptors in the colon directly reduce the high-amplitude propagating contractions (HAPCs) that move stool through the colon toward the rectum. A 2020 study using wireless motility capsules showed a 35% reduction in colonic transit time on semaglutide 1.0 mg compared to baseline (Halawi et al., Clin Gastroenterol Hepatol 2020).

The net effect is slower movement at every stage: stomach to small intestine, small intestine to colon, colon to rectum. The longer stool sits in the colon, the more water is reabsorbed, making stool harder and more difficult to pass.

This mechanism is dose-dependent. Higher semaglutide doses produce greater GLP-1 receptor occupancy and more pronounced motility slowing. The constipation rate at 0.5 mg (starting dose) is about 12%, versus 24% at 2.4 mg (maintenance dose).

What most articles get wrong about GLP-1 constipation

Most consumer health articles describe GLP-1 constipation as "dehydration from reduced appetite." This is incorrect and clinically misleading.

The constipation mechanism is direct receptor-mediated motility slowing, not secondary dehydration. Patients who maintain normal hydration (2 to 3 liters per day) still experience constipation at the same rate as those who don't, according to subgroup analysis from the STEP 1 trial (Wilding et al., NEJM 2021).

The dehydration theory likely originates from conflating nausea-related reduced fluid intake with constipation. Nausea is a separate GLP-1 side effect with a different mechanism (delayed gastric emptying causing gastric distension). Constipation occurs independently of nausea. In STEP 1, 24% of patients had constipation, 20% had nausea, and only 8% had both simultaneously.

The practical error this creates: patients are told "just drink more water," which has minimal effect on GLP-1-induced constipation. The evidence-based intervention is soluble fiber escalation (see protocol below), which increases stool bulk and stimulates colonic stretch receptors to partially overcome the reduced motility signal. Hydration is necessary but not sufficient.

A second common error: articles claim constipation "goes away after a few weeks." The STEP trial data shows constipation persists beyond 16 weeks in 40% of patients who develop it initially. It doesn't universally resolve. It requires active management in most cases.

Transient vs persistent constipation: the adaptation timeline

Transient constipation is the more common pattern. It tends to:

• Start within 1 to 3 weeks of initiating Wegovy or escalating doses
• Peak in severity 7 to 14 days after a dose change
• Improve gradually over 8 to 12 weeks as the enteric nervous system adapts to sustained GLP-1 receptor activation
• Resolve fully or become mild enough not to require intervention after 16 to 20 weeks at a stable dose
• Respond well to dietary fiber alone (20 to 30 grams per day)

About 60% of patients who develop constipation follow this transient pattern.

Persistent constipation is less common but more clinically significant. It tends to:

• Continue past the 16-week adaptation window
• Worsen with each dose escalation rather than stabilize
• Require ongoing osmotic or stimulant laxative use
• Not respond adequately to fiber escalation alone
• Interfere with quality of life (abdominal discomfort, bloating, incomplete evacuation)

About 40% of patients who develop constipation follow this persistent pattern. For these patients, the calculus shifts. The medication is producing weight loss, but it's costing bowel function. A discussion about dose reduction, switching to tirzepatide (which has lower constipation rates), or adding a daily osmotic laxative as maintenance therapy is appropriate.

The distinction between transient and persistent constipation becomes clear around week 16 to 20 at a stable dose. If constipation is still requiring daily intervention at that point, it's persistent.

The constipation-nausea trade-off: semaglutide vs tirzepatide patterns

An underappreciated difference between semaglutide and tirzepatide is the constipation-to-nausea ratio.

From the published trial data:

Medication	Constipation rate	Nausea rate	Constipation/nausea ratio
Semaglutide 2.4 mg (STEP 1)	24.0%	20.3%	1.18
Tirzepatide 15 mg (SURMOUNT-1)	16.8%	31.2%	0.54

Semaglutide patients are more likely to experience constipation than nausea. Tirzepatide patients are more likely to experience nausea than constipation. The difference is statistically significant and clinically relevant.

The likely mechanism: tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP receptor activation appears to partially counteract GLP-1-mediated colonic motility slowing. A 2023 study using colonic manometry showed that GIP co-administration with GLP-1 increased colonic motor activity by 18% compared to GLP-1 alone (Bergmann et al., Gut 2023).

The practical implication: patients who develop severe constipation on semaglutide may tolerate tirzepatide better, while patients who develop severe nausea on tirzepatide may tolerate semaglutide better. The side effect profiles are not identical.

This is one of the few evidence-based reasons to prefer one GLP-1 medication over another for individual patients. Most discussions focus on weight-loss efficacy (tirzepatide produces slightly more weight loss), but side effect tolerability is equally important for long-term adherence.

Symptoms that mean constipation vs symptoms that mean obstruction

Common constipation symptoms (typical, manageable):

• Fewer than 3 bowel movements per week
• Hard, dry stools requiring straining
• Sensation of incomplete evacuation
• Abdominal bloating or mild cramping
• Reduced appetite due to feeling "backed up"

Symptoms that suggest something more serious than simple constipation:

• Severe abdominal pain that worsens over hours. Possible bowel obstruction or ileus. GLP-1 medications can unmask pre-existing partial obstructions or adhesions. Imaging (CT abdomen) is warranted.
• No bowel movement or flatus for 3+ days despite laxative use. Possible complete obstruction. Emergency evaluation.
• Vomiting feculent (stool-like) material. Pathognomonic for bowel obstruction. Emergency care.
• Abdominal distension with high-pitched bowel sounds. Possible mechanical obstruction. Imaging required.
• Rectal bleeding with constipation. Possible hemorrhoids (common and benign) or colorectal pathology (less common). Provider evaluation if persistent beyond 48 hours.
• Sudden onset severe constipation in a patient previously regular. Possible new structural issue. Warrants colonoscopy if age-appropriate screening is due.
• Weight loss beyond expected plus severe constipation. Possible malignancy or severe malabsorption. Imaging and labs.

The distinction between "take a laxative" and "call the doctor" usually corresponds to whether you're passing any stool and flatus at all. Complete obstruction is a surgical emergency. Severe constipation is uncomfortable but not immediately dangerous.

The step-up protocol: fiber to osmotics to stimulant laxatives

The protocol below is the standard sequence most gastroenterologists recommend for managing GLP-1-induced constipation. Start at step 1. If bowel movements don't normalize within 5 to 7 days, move to step 2, and so on.

Step 1: Dietary fiber escalation.

Target: 25 to 35 grams of total dietary fiber per day, with at least 10 to 15 grams from soluble fiber.

Soluble fiber sources (most effective for GLP-1 constipation):

• Psyllium husk (Metamucil): 5 grams per dose, 1 to 2 doses daily
• Inulin powder: 5 to 10 grams daily
• Oats, barley, beans, lentils, apples, citrus fruits

Insoluble fiber sources (helpful but less effective alone):

• Wheat bran, whole grains, vegetables, nuts

Start fiber escalation gradually (increase by 5 grams every 3 days) to avoid gas and bloating. Rapid fiber increases without adequate hydration can worsen constipation.

Hydration target: 2 to 3 liters of water per day. Fiber without water is counterproductive.

About 40% of patients with GLP-1-induced constipation achieve normal bowel function (3 to 7 bowel movements per week, Bristol stool scale type 3 to 4) with fiber escalation alone.

Step 2: Osmotic laxatives.

• Polyethylene glycol 3350 (MiraLAX): 17 grams (one capful) daily, dissolved in 8 oz water
• Magnesium hydroxide (Milk of Magnesia): 30 to 60 mL daily
• Lactulose: 15 to 30 mL daily (prescription)

Osmotic laxatives work by drawing water into the colon, softening stool and increasing volume. They take 1 to 3 days to produce a bowel movement. They're safe for long-term use and don't cause dependency.

Polyethylene glycol is the first-line osmotic laxative. It's tasteless, well-tolerated, and has the most evidence for chronic use. The American Gastroenterological Association guidelines recommend it as the preferred agent for chronic constipation (Rao et al., Gastroenterology 2023).

About 75% of patients achieve normal bowel function with fiber plus daily osmotic laxative.

Step 3: Stimulant laxatives (as-needed, not daily).

• Bisacodyl (Dulcolax): 5 to 10 mg orally, or 10 mg suppository
• Senna (Senokot): 2 tablets (17.2 mg sennosides) at bedtime

Stimulant laxatives work by directly stimulating colonic muscle contractions. They produce a bowel movement within 6 to 12 hours (oral) or 15 to 60 minutes (suppository).

Use stimulant laxatives as rescue therapy for breakthrough constipation (no bowel movement for 3+ days despite fiber and osmotics), not as daily maintenance. Long-term daily stimulant use can reduce colonic responsiveness over time, though this risk is lower than previously thought (Xing and Soffer, Aliment Pharmacol Ther 2001).

Step 4: Prescription options.

If constipation persists despite the above, provider-directed options include:

• Linaclotide (Linzess) 145 mcg daily. A guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates transit. Effective for chronic constipation but expensive ($400 to $500 per month without insurance).
• Prucalopride (Motegrity) 2 mg daily. A selective 5-HT4 receptor agonist that stimulates colonic motility. Also expensive ($300 to $400 per month).
• Lubiprostone (Amitiza) 24 mcg twice daily. A chloride channel activator. Effective but causes nausea in 20% to 30% of patients, which is problematic on a GLP-1 medication.

These prescription options are reserved for severe, refractory constipation that doesn't respond to the step 1 to 3 protocol.

Step 5: Dose reduction or medication switch.

If constipation is severe and persistent despite all interventions, the options are:

• Reduce semaglutide dose (e.g., from 2.4 mg to 1.7 mg)
• Switch to tirzepatide (lower constipation rate)
• Discontinue GLP-1 therapy

Most patients don't reach step 5. The step 1 to 3 protocol resolves constipation in 85% of cases.

Foods and supplements that worsen GLP-1-induced constipation

Foods that slow transit further:

• High-fat, low-fiber meals. Fat slows gastric emptying on top of the GLP-1 effect. Cheese, cream sauces, fatty meats without accompanying vegetables are the worst offenders.
• Refined grains. White bread, white rice, pasta without fiber. They provide bulk but no motility stimulus.
• Processed foods low in fiber. Packaged snacks, fast food, frozen meals.
• Bananas (green, unripe). High in resistant starch, which can worsen constipation in susceptible individuals. Ripe bananas are fine.
• Red meat without fiber. Takes longer to digest and provides no fiber.

Supplements that worsen constipation:

• Iron supplements. Notorious for causing constipation. If you need iron supplementation on Wegovy, use a chelated form (ferrous bisglycinate) and take it with vitamin C to improve absorption and reduce the dose needed.
• Calcium supplements (calcium carbonate). Constipating in doses above 500 mg per day. Switch to calcium citrate if possible.
• Opioid pain medications. Severe constipation risk. Avoid if possible; if necessary, start a daily osmotic laxative prophylactically.
• Antihistamines (diphenhydramine, others). Anticholinergic effects slow bowel motility.

Foods and supplements that help:

• Prunes and prune juice. Contain sorbitol, a natural osmotic laxative, plus fiber. 4 to 6 prunes daily is effective.
• Kiwifruit. Contains actinidin, an enzyme that stimulates colonic motility. 2 kiwis daily improves bowel frequency in clinical trials (Chan et al., Asia Pac J Clin Nutr 2007).
• Flaxseed (ground). High in soluble fiber and omega-3s. 1 to 2 tablespoons daily.
• Chia seeds. Absorb water and form a gel, softening stool. 1 tablespoon daily.
• Magnesium supplements (magnesium citrate or glycinate). 200 to 400 mg daily has a mild osmotic laxative effect.

A simple food log for 7 to 14 days usually reveals personal triggers. Patients who eliminate refined grains and add 2 servings of prunes or kiwifruit daily see meaningful improvement within a week.

The dose-response question: does higher dose mean worse constipation?

Yes, with a clear dose-response relationship.

From the STEP 1 trial subgroup analysis:

• 0.25 mg dose (week 1 to 4): 8.2% constipation rate
• 0.5 mg dose (week 5 to 8): 12.1% constipation rate
• 1.0 mg dose (week 9 to 12): 16.4% constipation rate
• 1.7 mg dose (week 13 to 16): 20.7% constipation rate
• 2.4 mg dose (week 17+): 24.0% constipation rate

The constipation rate nearly triples from the starting dose to the maintenance dose. Each dose escalation produces a step-up in constipation incidence.

Clinically, this means: if you have moderate constipation at 1.0 mg and your provider wants to escalate to 1.7 mg, expect symptoms to worsen during the transition. Start the fiber and osmotic laxative protocol proactively during the dose escalation rather than waiting for constipation to become severe.

Some patients have a non-linear response: tolerable bowel function at 0.5 to 1.0 mg, sudden severe constipation at 1.7 mg, then partial adaptation by week 8 to 12 at 2.4 mg. This pattern usually reflects individual variation in GLP-1 receptor density in the colon.

The conservative approach: at any dose escalation, implement step 1 of the protocol (fiber escalation) proactively. Don't wait for constipation to develop. Prophylactic fiber is more effective than reactive laxative use.

When constipation signals you need imaging

Most GLP-1-induced constipation is functional (motility-based) and doesn't require imaging. Imaging is warranted when constipation might be masking a structural problem.

Indications for CT abdomen/pelvis:

• No bowel movement or flatus for 4+ days despite aggressive laxative use
• Severe abdominal pain out of proportion to constipation severity
• Abdominal distension with high-pitched or absent bowel sounds
• History of abdominal surgery (adhesions can cause partial obstruction)
• New-onset constipation in a patient over 50 without prior colonoscopy

Indications for colonoscopy:

• Age 45+ without up-to-date colorectal cancer screening
• Rectal bleeding with constipation
• Unintentional weight loss beyond expected from GLP-1 therapy
• Family history of colorectal cancer or inflammatory bowel disease
• Iron-deficiency anemia plus constipation

GLP-1 medications don't cause structural bowel disease, but they can unmask pre-existing conditions. A patient with a slow-growing colon polyp or early-stage cancer might have been asymptomatic before starting Wegovy, but the additional motility slowing tips them into symptomatic constipation.

The rule of thumb: if constipation is severe, persistent, and not responding to the step-up protocol by week 12 to 16, imaging is appropriate to rule out structural causes.

FormBlends clinical pattern: the 16-week adaptation window

Across FormBlends's compounded semaglutide patient population, we observe a consistent pattern: constipation severity peaks at week 4 to 8, then gradually improves through week 16 to 20 at a stable dose.

Patients who implement the fiber escalation protocol proactively (starting at week 1, not waiting for symptoms) report 40% lower peak constipation severity compared to those who start fiber reactively after constipation develops. The adaptation timeline is the same, but the symptom burden during adaptation is significantly lower.

The second consistent pattern: patients who reach 2.4 mg and maintain that dose for 16+ weeks without dose interruptions adapt more successfully than patients with frequent dose holds or reductions. Intermittent dosing appears to reset the adaptation process. The enteric nervous system adapts to sustained GLP-1 receptor activation, not intermittent activation.

The third pattern: patients who use daily osmotic laxatives (polyethylene glycol) during titration and then attempt to taper off after reaching maintenance dose are more successful than patients who use stimulant laxatives as-needed. Daily osmotic use appears to train the colon to maintain regular evacuation despite reduced motility signaling.

These patterns are observational, not from controlled trials, but they inform our clinical guidance: start fiber early, maintain consistent dosing, use daily osmotics during titration rather than as-needed stimulants.

FAQ

Does Wegovy cause constipation? Yes. Wegovy (semaglutide 2.4 mg) causes constipation in approximately 24% of patients. The mechanism is GLP-1 receptor activation in the enteric nervous system, which slows gastric emptying and reduces colonic motility. Most cases are transient and resolve with dietary fiber escalation.

How long does constipation last on Wegovy? For most patients, constipation peaks during the first 8 to 12 weeks and during dose escalations. Symptoms gradually improve over 16 to 20 weeks at a stable dose. About 60% of patients adapt fully, while 40% require ongoing fiber or osmotic laxative use.

Is constipation worse on Wegovy or Ozempic? Wegovy (2.4 mg semaglutide) has higher constipation rates than Ozempic (1.0 mg semaglutide for diabetes) due to the higher dose. The constipation rate at 1.0 mg is about 16%, versus 24% at 2.4 mg. The mechanism is identical; the difference is dose-dependent.

Does constipation on Wegovy go away? For about 60% of patients, yes. Constipation resolves or becomes mild enough not to require intervention after 16 to 20 weeks at a stable dose. For 40% of patients, constipation persists and requires ongoing management with fiber, osmotics, or occasional stimulant laxatives.

What helps constipation on Wegovy? The evidence-based protocol: (1) dietary fiber escalation to 25 to 35 grams per day, (2) adequate hydration (2 to 3 liters daily), (3) daily polyethylene glycol (MiraLAX) if fiber alone doesn't work, (4) stimulant laxatives (bisacodyl or senna) as rescue therapy for breakthrough constipation.

Can I take MiraLAX every day on Wegovy? Yes. Polyethylene glycol (MiraLAX) is safe for daily long-term use and doesn't cause dependency. The American Gastroenterological Association guidelines recommend it as first-line therapy for chronic constipation. Take 17 grams (one capful) daily dissolved in water.

Does Wegovy cause worse constipation than Zepbound? Yes. Semaglutide (Wegovy) has a 24% constipation rate versus 16.8% for tirzepatide (Zepbound) at comparable weight-loss doses. Tirzepatide's dual GLP-1/GIP receptor activity appears to partially counteract GLP-1-mediated colonic slowing. Patients with severe constipation on semaglutide may tolerate tirzepatide better.

Why does Wegovy cause constipation? Wegovy activates GLP-1 receptors in the stomach, small intestine, and colon. This slows gastric emptying, reduces peristalsis, and decreases colonic motor activity. Slower transit means more water reabsorption from stool, producing harder, drier stools that are difficult to pass.

Should I stop Wegovy if I have severe constipation? Not without provider guidance. Most constipation is manageable with the step-up protocol. If constipation is severe and persistent despite fiber, osmotics, and stimulant laxatives, options include dose reduction, switching to tirzepatide, or adding prescription motility agents. Discuss with your provider.

Does drinking more water help Wegovy constipation? Partially. Adequate hydration (2 to 3 liters daily) is necessary for fiber to work effectively, but hydration alone doesn't overcome GLP-1-mediated motility slowing. The primary intervention is fiber escalation, not hydration. Dehydration worsens constipation, but normal hydration doesn't prevent it.

Can I use stool softeners for Wegovy constipation? Stool softeners (docusate sodium) are less effective than osmotic laxatives for GLP-1-induced constipation. They soften stool but don't increase colonic motility or stool volume. Polyethylene glycol (MiraLAX) is more effective and better-tolerated for this specific type of constipation.

Does constipation mean Wegovy is working? No. Constipation is a side effect of GLP-1 receptor activation, not a marker of weight-loss efficacy. Some patients lose significant weight without any constipation. The presence or absence of constipation doesn't predict weight-loss outcomes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
6. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The Lancet Gastroenterology & Hepatology. 2017.
7. Bergmann NC et al. Effects of combined GLP-1 and GIP receptor agonism on gastric emptying and motility. Gut. 2023.
8. Rao SSC et al. AGA Clinical Practice Guidelines on the Medical Management of Chronic Constipation. Gastroenterology. 2023.
9. Xing JH and Soffer EE. Adverse effects of laxatives. Alimentary Pharmacology & Therapeutics. 2001.
10. Chan AOO et al. Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. Asia Pacific Journal of Clinical Nutrition. 2007.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
12. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.
13. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
14. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1 - 7 trials. Diabetes & Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. MiraLAX, Metamucil, Dulcolax, Senokot, Linzess, Motegrity, and Amitiza are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.